{"id":"NCT02931539","sponsor":"Shire","briefTitle":"Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir","officialTitle":"A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-22","primaryCompletion":"2020-08-17","completion":"2020-08-17","firstPosted":"2016-10-13","resultsPosted":"2021-09-23","lastUpdate":"2021-11-03"},"enrollment":352,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cytomegalovirus (CMV)"],"interventions":[{"type":"DRUG","name":"Maribavir","otherNames":["SHP620"]},{"type":"DRUG","name":"Ganciclovir","otherNames":[]},{"type":"DRUG","name":"Valganciclovir","otherNames":[]},{"type":"DRUG","name":"Foscarnet","otherNames":[]},{"type":"DRUG","name":"Cidofovir","otherNames":[]}],"arms":[{"label":"Maribavir Treatment","type":"EXPERIMENTAL"},{"label":"Investigator-Assigned Treatment","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) (CMV Viremia Clearance) at End of Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Investigator-assigned Anti-CMV Treatment (IAT)","deltaMin":23.9,"sd":null},{"arm":"Maribavir 400 mg","deltaMin":55.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":134,"countries":["United States","Australia","Austria","Belgium","Canada","Croatia","Denmark","France","Germany","Italy","Singapore","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["40478680","39613120","38071422","37506264","34864943","33811823"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fd74db2bf003ab46f3d"]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":56},"commonTop":["Diarrhoea","Nausea","Dysgeusia","Neutropenia","Vomiting"]}}